Predictors of progression in patients with Friedreich ataxia

Movement Disorders

Volumn 23, Issue 14, 2008, Pages 2026-2032

  La Pean, Alison ^a   Jeffries, Neal ^a   Grow, Chelsea ^b   Ravina, Bernard ^c   di Prospero, Nicholas A ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Memorial Neurosciences Department   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Friedreich ataxia; GAA expansion; Genotype; Medication; Phenotype

Indexed keywords

ACETYLCYSTEINE; ADENINE; ALPHA TOCOPHEROL; ASCORBIC ACID; CREATINE; FRATAXIN; GUANINE; IDEBENONE; THIOCTIC ACID; UBIDECARENONE; VITAMIN;

ADL DISABILITY; ADOLESCENT; ADULT; ALLELE; ARTICLE; CARDIOMYOPATHY; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; FEMALE; FRIEDREICH ATAXIA; HEREDITY; HUMAN; IMMOBILIZATION; INHERITANCE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OXIDATIVE STRESS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCOLIOSIS; TRINUCLEOTIDE REPEAT;

ADOLESCENT; ADULT; AGED; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FEMALE; FRIEDREICH ATAXIA; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SCOLIOSIS; VITAMINS; YOUNG ADULT;

EID: 57049116558     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22248     Document Type: Article

References (24)

1. Delatycki MB, Williamson R, Forrest SM. Friedreich ataxia: an overview. J Med Genet 2000;37:1-8.
2. Geoffroy G, Barbeau A, Breton G, et al. Clinical description and roentgenologic evaluation of patients with Friedreich's ataxia. Can J Neurol Sci 1976;3:279-286.
3. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intra-familial clustering of clinical features. Brain 1981;104:589-620.
4. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
5. Cossee M, Durr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45:200-206.
6. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997;6:1771-1780.
7. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997;276:1709-1712.
8. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997;17:215-217.
9. Cooper JM, Schapira AH. Friedreich's ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. Biofactors 2003; 18:163-171.
10. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996; 335:1169-1175.
11. Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996;59:554-560.
12. Delatycki MB, Paris DB, Gardner RJ, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet 1999;87:168-174.
13. Mateo I, Llorca J, Volpini V, Corral J, Berciano J, Combarros O. Expanded GAA repeats and clinical variation in Friedreich's ataxia. Acta Neurol Scand 2004;109:75-78.
14. De Castro M, Garcia-Planells J, Monros E, et al. Genotype and phenotype analysis of Friedreich's ataxia compound heterozygous patients. Hum Genet 2000;106:86-92.
15. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
16. Klockgether T, Ludtke R, Kramer B, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 1998;121 (Part 4):589-600.
17. Lamont PJ, Davis MB, Wood NW. Identification and sizing of the GAA trinucleotide repeat expansion of Friedreich's ataxia in 56 patients. Clinical and genetic correlates. Brain 1997;120(Part 4):673-680.
18. De Michele G, Filla A, Criscuolo C, et al. Determinants of onset age in Friedreich's ataxia. J Neurol 1998;245:166-168.
19. Schols L, Amoiridis G, Przuntek H, Frank G, Epplen JT, Epplen C. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain 1997;120(Part 12):2131-2140.
20. Ribai P, Pousset F, Tanguy ML, et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 2007;64:558-564.
21. Lodi R, Rajagopalan B, Bradley JL, et al. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives. Free Radic Res 2002;36:461-466.
22. Calabrese V, Lodi R, Tonon C, et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci 2005;233:145-162.
23. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999;354:477-479.
24. Myers L, Farmer JM, Wilson RB, et al. Antioxidant use in Friedreich ataxia. J Neurol Sci 2008;267:174-176.